PatientsVille.com Logo

HAEMATOCHEZIA and ZOCOR

PatientsVille

HAEMATOCHEZIA Symptoms and Causes

Your digestive or gastrointestinal (GI) tract includes the esophagus, stomach, small intestine, large intestine or colon, rectum, and anus. Bleeding can come from any of these areas. The amount of bleeding can be so small that only a lab test can find it.

Signs of bleeding in the digestive tract depend where it is and how much bleeding there is.

Signs of bleeding in the upper digestive tract include

  • Bright red blood in vomit
  • Vomit that looks like coffee grounds
  • Black or tarry stool
  • Dark blood mixed with stool

Signs of bleeding in the lower digestive tract include

  • Black or tarry stool
  • Dark blood mixed with stool
  • Stool mixed or coated with bright red blood

GI bleeding is not a disease, but a symptom of a disease. There are many possible causes of GI bleeding, including hemorrhoids, peptic ulcers, tears or inflammation in the esophagus, diverticulosis and diverticulitis, ulcerative colitis and Crohn's disease, colonic polyps, or cancer in the colon, stomach or esophagus.

The test used most often to look for the cause of GI bleeding is called endoscopy. It uses a flexible instrument inserted through the mouth or rectum to view the inside of the GI tract. A type of endoscopy called colonoscopy looks at the large intestine.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for HAEMATOCHEZIA

HAEMATOCHEZIA treatment research studies

ZOCOR clinical trials, surveys and public health registries


Find Drug Side Effect reports



ZOCOR Side Effects

Rhabdomyolysis (1045)
Myalgia (844)
Blood Creatine Phosphokinase Increased (494)
Asthenia (430)
Muscular Weakness (393)
Renal Failure Acute (366)
Pain In Extremity (328)
Arthralgia (302)
Muscle Spasms (284)
Fatigue (263)
Myopathy (253)
Renal Failure (231)
Pain (228)
Dyspnoea (220)
Myocardial Infarction (202)
Myositis (201)
Nausea (196)
Alanine Aminotransferase Increased (184)
Chest Pain (179)
Dizziness (178)
Fall (128)
Aspartate Aminotransferase Increased (127)
Malaise (122)
Cerebrovascular Accident (120)
Diarrhoea (119)
Headache (104)
Back Pain (101)
Liver Function Test Abnormal (101)
Depression (100)
Abdominal Pain (95)
Gait Disturbance (93)
Blood Creatinine Increased (93)
Anxiety (92)
Abasia (91)
Vomiting (87)
Amnesia (86)
Abdominal Pain Upper (79)
Anaemia (78)
Coronary Artery Disease (76)
Insomnia (75)
Cardiac Failure Congestive (74)
Weight Decreased (73)
Dehydration (72)
Pyrexia (71)
Confusional State (70)
Paraesthesia (70)
Hypertension (69)
Pneumonia (69)
Rash (68)
Cardiac Disorder (67)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

HAEMATOCHEZIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Validation of an Alternative Biological Test to Increase the Detection Sensitivity of a Colon Tumour
Condition: Colorectal Cancer
Intervention: Device: COLOHYBRITEST OR VALIHYBRITEST
Outcome Measures: To determine the performances (sensitivity, specificity and likelihood ratios) of a panel of blood and/or faecal molecular DNA markers;   To estimate the cost and cost-effectiveness of adding DNA molecular tests to FOBT positive patients prior to colonoscopy;   To determine the performances (sensitivity, specificity and likelihood ratios) of a panel of blood and/or faecal molecular protein markers;   To create biological collections for screening purposes (asymptomatic subjects)
2 Recruiting Aspiration of Residual Gastric Contents
Conditions: Infant, Premature;   Nutrition, Enteral
Interventions: Procedure: No aspiration of gastric contents;   Procedure: Routine aspiration of gastric contents
Outcome Measures: 24-hour enteral feeding intake in mL/kg;   Time to reach full feeds;   Hours receiving parenteral nutrition;   Weekly or biweekly liver function tests;   Hours of central venous line access;   Episodes of late onset sepsis;   Growth indices;   Length of hospital stay;   Episodes of necrotizing enterocolitis;   Presence of blood in stools;   Level of fecal calprotectin;   serum gastrin level;   motilin level;   tracheal pepsin levels;   presence of aspiration pneumonia;   presence of ventilator associated pneumonia
3 Recruiting A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: VSL#3
Outcome Measures: to evaluate the effect of a probiotic formulation, VSL#3, versus placebo, on metabolic profile, intestinal permeability, microbiota, cytokines and chemokines expression and other inflammatory markers in pediatric patients with Crohn's Disease;   To determine the effect on Pediatric Crohn Disease Activity Index (PCDAI);;   to determine the time till flare of CD pediatric patients on VSL#3 compared to placebo.
4 Recruiting TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)
Condition: Active Ulcerative Colitis
Interventions: Drug: Mesalazine - TID 1000 mg;   Drug: Mesalazine - TID 2x 500 mg
Outcome Measures: Rate of clinical remission;   Number of stools per week;   Number of bloody stools per week;   Time to first resolution of clinical symptoms
5 Unknown  Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis for Variceal Bleeding
Conditions: Esophageal and Gastric Varices;   Gastrointestinal Hemorrhage
Intervention: Drug: ceftrioxone
Outcome Measures: rebleeding rate within 14 days;   motarlity rate within 28 days